Researchers Database

SODA SAYO

Affiliation： Department of Pulmonary Medicine and Clinical Immunology

Last Updated :2024/05/23

Original paper

間質性肺炎患者における筋炎関連自己抗体の陽性率と治療反応性及び予後についての検討., 森田弘子, 伊藤紘, 清水悠佳, 正和明哲, 中村祐介, 小池亮介, 奥冨泰明, 渡邊泰治, 横山達也, 曾田紗世, 塩原太一, 池田直哉, 新井良, 知花和行, 武政聡浩, 倉沢和宏, 清水泰生, DJMS, 47, 105, 2020

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma., Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R, Takigami A, Sata M, Thorac Cancer, 11(4), 935-942, Feb. 2020
DOI

Auto-antibody evaluation in idiopathic interstitial pneumonia and worse survival of patients with Ro52/TRIM21auto-antibody., Morita H, Shimizu Y, Nakamura Y, Okutomi H, Watanabe T, Yokoyama T, Soda S, Ikeda N, Shiobara T, Miyoshi M, Chibana K, Takemasa A, Kurasawa K, J Clin Biochem Nutr, 67(2), 199-205, Sep. 2020
DOI

A case of spindle cell dominant histiocytic sarcoma showing a complete remission after first-line chemotherapy with doxorubicin and ifosfamide., Nakamura Y, Takemasa A, Kushima Y, Soda S, Ikeda N, Arai R, Chibana K, Nakazato Y, Yokose T, Shimizu Y, Niho S, J Chemother, 20, 1-6, Nov. 2020
DOI

Other

Unclear

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma., Kishikawa Takayuki;Kasai Takashi;Okada Masahiko;Nakachi Ichiro;Soda Sayo;Arai Ryo;Takigami Ayako;Sata Masafumi, Thoracic cancer, 11(4), 935-942, 2020
DOI Permalink

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma., Kishikawa Takayuki;Kasai Takashi;Okada Masahiko;Nakachi Ichiro;Soda Sayo;Arai Ryo;Takigami Ayako;Sata Masafumi, Thoracic cancer, 11(4), 935-942, 2020
DOI Permalink

Auto-antibody evaluation in idiopathic interstitial pneumonia and worse survival of patients with Ro52/TRIM21auto-antibody., Morita Hiroko;Shimizu Yasuo;Nakamura Yusuke;Okutomi Hiroaki;Watanabe Taiji;Yokoyama Tatsuya;Soda Sayo;Ikeda Naoya;Shiobara Taichi;Miyoshi Masaaki;Chibana Kazuyuki;Takemasa Akihiro;Kurasawa Kazuhiro, Journal of clinical biochemistry and nutrition, 67(2), 199-205, Sep. 2020
DOI Permalink

Auto-antibody evaluation in idiopathic interstitial pneumonia and worse survival of patients with Ro52/TRIM21auto-antibody., Morita Hiroko;Shimizu Yasuo;Nakamura Yusuke;Okutomi Hiroaki;Watanabe Taiji;Yokoyama Tatsuya;Soda Sayo;Ikeda Naoya;Shiobara Taichi;Miyoshi Masaaki;Chibana Kazuyuki;Takemasa Akihiro;Kurasawa Kazuhiro, Journal of clinical biochemistry and nutrition, 67(2), 199-205, Sep. 2020
DOI Permalink

Changing patterns of pulmonary abnormalities in rheumatoid arthritis., Tanaka Ayae;Kurasawa Kazuhiro;Soda Sayo;Takamura Yuta;Miyao Tomoyuki;Hasegawa Anna;Hiyama Tomoka;Yamazaki Ryutaro;Arai Satoko;Owada Takayoshi;Arima Masafumi;Arakawa Hiroaki;Maezawa Reika, Respiratory investigation, 61(1), 27-39, 04 Oct. 2022
DOI

Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study., Ikeda Naoya;Arai Ryo;Soda Sayo;Inoue Takashi;Uchida Nobuhiko;Nakamura Yusuke;Masawa Meitetsu;Kushima Yoshitomo;Okutomi Hiroaki;Takemasa Akihiro;Shimizu Yasuo;Niho Seiji, Thoracic cancer, 13(9), 1342-1348, 22 Mar. 2022
DOI

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study., Mimori Tomoyasu;Shukuya Takehito;Ko Ryo;Okuma Yusuke;Koizumi Tomonobu;Imai Hisao;Takiguchi Yuichi;Miyauchi Eisaku;Kagamu Hiroshi;Sugiyama Tomohide;Azuma Keisuke;Namba Yukiko;Yamasaki Masahiro;Tanaka Hisashi;Takashima Yuta;Soda Sayo;Ishimoto Osamu;Koyama Nobuyuki;Kobayashi Kunihiko;Takahashi Kazuhisa, Cancers, 14(2), 11 Jan. 2022
DOI